WHO Urges Rapid Access to Mpox Diagnostic Tests

WHO Calls for Emergency Review of Mpox Diagnostic Tests

In response to the growing global concern over mpox, the World Health Organization (WHO) has issued an urgent call to diagnostic test manufacturers to submit their products for emergency review. This move is part of a broader effort to ensure that countries, particularly those with limited resources, have rapid access to effective diagnostic tools.

Global Demand for Accurate Testing Surges

With the emergence of a new form of the mpox virus, which has been confirmed in countries outside of its typical range such as Sweden and Thailand, the need for reliable diagnostic tests has never been more critical. The WHO declared mpox a global public health emergency earlier this month, following a surge in suspected cases, particularly in the Democratic Republic of Congo, where over 1,000 cases were reported in just one week.

Expanding Access to Testing

To meet the urgent need for testing, the WHO is streamlining its Emergency Use Listing process, allowing for the rapid approval of medical products, including diagnostic tests. This will enable countries to quickly procure the necessary tools through UN agencies and other partners. The organization has already committed to delivering 30,000 diagnostic tests to African nations in the coming weeks.

Collaboration with Global Manufacturers

The WHO has been actively engaging with manufacturers of in-vitro diagnostics, urging them to provide data on the quality, safety, and performance of their tests as quickly as possible. Companies like Labcorp and Swiss drugmaker Roche are already working with health regulators to enhance their testing capacities. The WHO’s updated diagnostic testing guidance will play a crucial role in detecting the new virus strain and ensuring that testing protocols are effectively implemented.

Conclusion

As the mpox outbreak continues to evolve, the WHO's swift action to secure and distribute diagnostic tests is vital for controlling the spread of the virus. By accelerating the review process and collaborating with global manufacturers, the organization aims to provide countries with the necessary tools to accurately diagnose and manage mpox cases, ultimately protecting public health on a global scale.